Koepsell E, Zumpe P, Saavedra C, Seidl S
Blutspendedienst Hessen des DRK, Institut Frankfurt am Main, BRD.
Beitr Infusionsther. 1992;30:416-9.
In a retrospective study we investigated the development of HLA antibodies in patients who received platelet concentrates from cell separators. 118 hematological/oncological patients from the Frankfurt University Clinics were investigated. They received between 4 and 66 platelet concentrates for the duration of 30 months. All patients had a negative antibody screening on admission. 31% developed either transient (15%) or permanent (16%) lymphocytotoxic antibodies. The increasing number of platelet transfusions did not correlate with the development of HLA antibodies, but the appearance of these antibodies seemed to be dependent on the disease. Permanent antibodies appeared in 8% of patients with acute leukemia, whereas 38% of patients suffering from CL, lymphoma, MDS and myeloma produced antibodies. Some patients (18) received granulocyte transfusions as well. It is striking that 11% of these patients developed permanent and 28% transient HLA antibodies. There exist no data about recent transfusions or previous pregnancies. To lower the rate of sensitization in patients with diseases such as CL, lymphoma, MDS and myeloma, it should be discussed whether leukocyte-depleted platelet concentrates should be given to these patients.
在一项回顾性研究中，我们调查了接受细胞分离器采集的血小板浓缩物的患者中HLA抗体的产生情况。对来自法兰克福大学诊所的118例血液学/肿瘤学患者进行了调查。在30个月的时间里，他们接受了4至66次血小板浓缩物输注。所有患者入院时抗体筛查均为阴性。31%的患者产生了短暂性（15%）或永久性（16%）淋巴细胞毒性抗体。血小板输注次数的增加与HLA抗体的产生无关，但这些抗体的出现似乎取决于疾病。8%的急性白血病患者产生了永久性抗体，而患有慢性淋巴细胞白血病（CL）、淋巴瘤、骨髓增生异常综合征（MDS）和骨髓瘤的患者中有38%产生了抗体。一些患者（18例）还接受了粒细胞输注。值得注意的是，这些患者中有11%产生了永久性HLA抗体，28%产生了短暂性HLA抗体。没有关于近期输血或既往妊娠的相关数据。为了降低CL、淋巴瘤、MDS和骨髓瘤等疾病患者的致敏率，应讨论是否应为这些患者输注白细胞去除的血小板浓缩物。
